Pharmaceutical funding of Australian patient groups was concentrated in a relatively small set of recipients in a study of 2013–2022 disclosures. The researchers report A$95.7 million across the decade, expressed in 2022 Australian dollars. This is a historical analysis published in October 2026, not a count of payments made this year. Original study
The findings raise two different transparency questions: where the money went, and how much a recipient depended on it. A large payment total and a large share of an organisation’s income are not the same measure.
Concentration is different from reliance
The paper identified 45 companies and 390 recipient groups. Thirteen groups received A$45.9 million—47.9% of the total. Separately, for the 132 groups funded in 2022, nine received more than half their estimated income from pharmaceutical companies. The latter figure is about reliance in one year, not the distribution of money over the whole decade. Results and income analysis
A simple example explains the distinction. The same donation could be a modest share of a large organisation’s income or most of a small organisation’s income. The example is arithmetic, not a description of any named group. It is why a list sorted only by payment size would answer an incomplete question.
The University of Sydney’s 20 October account foregrounds the scale and transparency implications of this work. It reports the same research; it is not a second measurement or evidence that the payments changed advocacy. Institutional account
What the disclosure framework asks for
Medicines Australia describes patient organisations as not-for-profit groups representing patients and caregivers. Its reporting page calls for the recipient’s name, a sufficiently clear description of the support, and the monetary value of financial support and invoiced costs. Significant support without a meaningful monetary value should instead be described. Industry reporting guidance
The industry body also identifies independence, public trust, fairness, transparency and accountability as principles for these relationships. That is its stated framework; it does not establish that every historical relationship was fully reported or independently assessed.
For someone reading a group’s policy position, a useful disclosure connects the funder, the period and the nature of support. A donor name alone can leave the scale or purpose unclear. Equally, a declared relationship should not automatically be treated as proof that a position was purchased.
What the figures cannot show
The study relied on available disclosures and a changing company set. Its recipient definition was broad. To estimate 2022 income, the researchers also had to align calendar-year payments with financial-year accounts, including averaging adjacent years. The resulting ratios are estimates, not perfectly matched cash-flow measures. Methods and limitations
Those limits constrain comparisons between individual groups and across time. The data describe disclosed financial relationships; they do not establish misconduct or isolate funding’s effect on advocacy. The supported policy question is how to make those relationships easier to understand without turning a funding total into an accusation.